ArticleFrontiers in oncology2026
Development of a multidimensional disease burden assessment system for childhood neuroblastoma based on the social determinants of health theory.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To construct a multidimensional disease burden assessment system for children with neuroblastoma based on the Social Determinants of Health (SDH) theory, and to provide a reference for targeted assistance for rare diseases and for the optimization of health resource allocation. Methods: An indicator pool was initially developed based on the SDH framework through a structured literature review and a structured expert panel discussion. From November to December 2025, 20 of the 21 invited experts participated in two rounds of Delphi consultation to finalize the indicators, and the Analytic Hierarchy Process was employed to calculate indicator weights. Results: The effective response rates of the 2 rounds of questionnaire surveys were 95.23% (20/21) and 100% (20/20), respectively. The expert authority coefficient was 0.885, and Kendall's W coefficients were 0.123-0.452 and 0.118-0.236 for the 2 rounds (all P < 0.05), indicating high expert coordination. The constructed indicator system comprised 3 first-level indicators [personal disease burden (0.3325), family disease burden (0.5278), and social disease burden (0.1396)], 8 second-level indicators, and 32 third-level indicators. Conclusion: The indicator system constructed in this study is a preliminary, theory-driven framework supported by expert consensus and internally consistent weighting. It can provide a reference for health administrative departments to identify high-burden families and formulate assistance policies, thereby supporting health governance across the full care cycle for children with rare diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.